Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

RYTM – Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals, Inc.
RYTM
$100.71
Name : Rhythm Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $6,721,155,072.00
EPSttm : -3.1
finviz dynamic chart for RYTM
Rhythm Pharmaceuticals, Inc.
$100.71
1.31%
$1.30

Float Short %

8.44

Margin Of Safety %

Put/Call OI Ratio

0.49

EPS Next Q Diff

0.06

EPS Last/This Y

1.25

EPS This/Next Y

0.81

Price

99.42

Target Price

126.31

Analyst Recom

1.27

Performance Q

1.35

Relative Volume

1.24

Beta

2

Ticker: RYTM




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20RYTM112.390.110.013575
2025-10-21RYTM107.10.100.213626
2025-10-22RYTM109.010.110.353656
2025-10-23RYTM109.030.110.023681
2025-10-24RYTM110.50.110.033706
2025-10-27RYTM111.420.110.803784
2025-10-28RYTM113.580.100.003777
2025-10-29RYTM113.780.100.403764
2025-10-30RYTM111.770.110.603770
2025-10-31RYTM113.760.110.633772
2025-11-03RYTM113.720.110.053773
2025-11-04RYTM104.990.115.083824
2025-11-05RYTM99.560.350.214727
2025-11-06RYTM98.570.359.754745
2025-11-07RYTM100.420.361.474771
2025-11-10RYTM97.630.400.004927
2025-11-11RYTM99.660.400.004935
2025-11-12RYTM97.970.4017.414930
2025-11-13RYTM95.870.480.505240
2025-11-14RYTM99.430.490.165243
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20RYTM112.39-0.4- -2.94
2025-10-21RYTM107.02-0.4- -2.94
2025-10-22RYTM109.17-0.4- -2.94
2025-10-23RYTM109.12-0.4- -2.94
2025-10-24RYTM110.51-0.5- -2.95
2025-10-27RYTM111.55-0.5- -2.95
2025-10-28RYTM113.46-0.5- -2.95
2025-10-29RYTM113.91-0.5- -2.95
2025-10-30RYTM111.81-0.5- -2.95
2025-10-31RYTM113.76-0.5- -2.95
2025-11-03RYTM113.77-0.5- -2.95
2025-11-04RYTM105.11-0.5- -2.95
2025-11-05RYTM99.54-0.5- -2.95
2025-11-06RYTM98.57-0.5- -2.95
2025-11-07RYTM100.30-2.1- -2.94
2025-11-10RYTM97.63-11.1- -2.94
2025-11-11RYTM99.86-11.1- -3.05
2025-11-12RYTM97.98-11.1- -3.05
2025-11-13RYTM95.82-10.7- -3.09
2025-11-14RYTM99.42-10.7- -3.09
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20RYTM-5.332.949.08
2025-10-21RYTM-5.592.949.08
2025-10-22RYTM-5.592.949.08
2025-10-23RYTM-5.592.949.08
2025-10-24RYTM-5.592.949.08
2025-10-27RYTM-5.593.049.08
2025-10-28RYTM-5.593.049.08
2025-10-29RYTM-5.573.049.08
2025-10-30RYTM-5.623.049.08
2025-10-31RYTM-5.623.049.08
2025-11-03RYTM-5.574.159.08
2025-11-04RYTM-5.574.159.08
2025-11-05RYTM-5.164.159.08
2025-11-06RYTM-5.574.159.08
2025-11-07RYTM-5.554.159.03
2025-11-10RYTM-5.556.709.03
2025-11-11RYTM-5.556.709.03
2025-11-12RYTM-5.956.708.48
2025-11-13RYTM-5.956.708.48
2025-11-14RYTM-5.956.708.44
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.82

Avg. EPS Est. Current Quarter

-0.8

Avg. EPS Est. Next Quarter

-0.77

Insider Transactions

-5.95

Institutional Transactions

6.7

Beta

2

Average Sales Estimate Current Quarter

55

Average Sales Estimate Next Quarter

56

Fair Value

Quality Score

45

Growth Score

39

Sentiment Score

59

Actual DrawDown %

14.3

Max Drawdown 5-Year %

-92.1

Target Price

126.31

P/E

Forward P/E

PEG

P/S

38.06

P/B

44.55

P/Free Cash Flow

EPS

-3.1

Average EPS Est. Cur. Y​

-3.09

EPS Next Y. (Est.)

-2.28

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-113.41

Relative Volume

1.24

Return on Equity vs Sector %

-93.8

Return on Equity vs Industry %

-79

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.14

EBIT Estimation

Rhythm Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 283
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
stock quote shares RYTM – Rhythm Pharmaceuticals Inc. Stock Price stock today
news today RYTM – Rhythm Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RYTM – Rhythm Pharmaceuticals Inc. yahoo finance google finance
stock history RYTM – Rhythm Pharmaceuticals Inc. invest stock market
stock prices RYTM premarket after hours
ticker RYTM fair value insiders trading